Skip to main content

Table 1 Comparison of patient characteristics between the AZA-001 trial and the EORTC 0611 trial for high-risk MDS

From: A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers

  AZA-001 trial: azacitidine EORTC 0611 trial: decitabine
Eligibility criteria IPSS INT2/high IPSS INT1/INT2/high
  MDS with 5–30 % blasts MDS with 11–30 % blasts or <10 % blasts and poor cytogenetics
  CMML with >10 % blasts and WBC <13 G/L CMML independent of blast counts or WBC counts
  No t-MDS allowed t-MDS allowed
Treatment schedule 75 mg/m2 days 1–7, q28 15 mg/m2 3× day q42
  Treatment until progression Maximum number of 8 cycles
Patient cohort   
 IPSS high 46 % 38.70 %
 Poor cytogenetics 28 % 48 %
 t-MDS 0 12.60 %
Median cycle number 9 4